- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approval August 2022, EMA June 2022, Japan March 2022).
- Why 3/10
- Xenpozyme is already approved and marketed with no pending regulatory decision or pivotal readout. It is a very small part of Sanofi's diversified portfolio (EUR 38 million in 2024 sales vs. Sanofi's EUR 46.7 billion total 2025 revenue). Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5, and the minimal concentration at Sanofi places it at the low end.
Xenpozyme is already approved and commercializing with no pending regulatory decisions or pivotal readouts. The next catalyst to watch would be Sanofi's full-year 2026 earnings (expected early February 2027) for Xenpozyme's annual sales growth trajectory. For a diversified giant like Sanofi, Xenpozyme's performance is unlikely to be a material stock-moving event on its own.
Price Chart
Executive Summary
Xenpozyme (olipudase alfa) is Sanofi's enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease types A/B and B), an ultra-rare genetic disorder affecting fewer than 120 people in the U.S. It was first approved globally in Japan (March 2022), then by the FDA (August 2022) and EMA (June 2022) as the first and only disease-specific treatment for non-CNS manifestations of ASMD in adult and pediatric patients. A pediatric label expansion (sBLA) was approved in 2024. Xenpozyme generated EUR 38 million in 2024 sales (up 50% YoY), but is a very small component of Sanofi's overall portfolio (Sanofi Q3 2026 sales were EUR 14.4 billion). No near-term binary catalysts exist for this drug.
How It Works
Xenpozyme is an enzyme replacement therapy. Patients with ASMD are born with a genetic defect that prevents their bodies from producing a working version of an enzyme called acid sphingomyelinase (ASM). Without this enzyme, a fatty substance called sphingomyelin builds up in cells, damaging organs like the lungs, liver, and spleen. Xenpozyme is a lab-made version of the missing enzyme, delivered intravenously (by IV infusion) every two weeks, that breaks down the accumulated fatty material.
Trial Status
Xenpozyme was approved based on the Phase 2/3 ASCEND trial (placebo-controlled in 31 adults) and the ASCEND-Peds open-label trial (8 pediatric patients). Both showed improvements in lung function (DLco) and reductions in spleen and liver volumes. A Phase 2 extension study in France (NCT06949358) completed in April 2025. The FDA approved a pediatric label expansion via sBLA in 2024.
The Two-Sided Case
Upcoming Catalysts
- No near-term binary catalysts for Xenpozyme specifically. The drug is already approved and commercializing. Sanofi's full-year 2026 earnings (expected early February 2027) will include Xenpozyme's annual sales figures.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report